MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, OLMA had -$91,179K decrease in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
-$91,179K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of marketable securit...
    • Proceeds from issuance of shares...
    • Stock-based compensation expense...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Net loss
    • Payment of issuance costs for sh...
    • Others

Cash Flow
2025-12-31
Net loss
-162,451
Depreciation and amortization expense
490
Non-cash lease expense
1,176
Non-cash interest income on marketable securities
-6,292
Stock-based compensation expense, including employee stock purchase plan expense
17,586
Prepaid expenses and other current assets
5,418
Other assets and long-term deposits
6,145
Accounts payable
4,598
Other current liabilities
10,984
Operating lease liabilities
-1,244
Net cash used in operating activities
-146,716
Maturities of marketable securities
344,962
Purchases of marketable securities
500,722
Net cash used in investing activities
-155,760
Proceeds from issuance of shares upon follow-on public offering, net of issuance costs of 13,110
205,390
Payment of issuance costs for shares issued under 2024 private placement
6,514
Proceeds from borrowings under credit facility (note 13)
3,000
Proceeds from exercise of stock options
8,391
Proceeds from issuance of common stock under employee stock purchase plan
1,030
Net cash provided by financing activities
211,297
Net (decrease) increase in cash and cash equivalents
-91,179
Cash and cash equivalents at beginning of period
139,480
Cash and cash equivalents at end of period
48,301
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance ofshares upon follow-on...$205,390K Proceeds from exercise ofstock options$8,391K Proceeds from borrowingsunder credit facility...$3,000K Proceeds from issuance ofcommon stock under...$1,030K Net cash provided byfinancing activities$211,297K Canceled cashflow$6,514K Net (decrease)increase in cash and cash...-$91,179K Canceled cashflow$211,297K Maturities of marketablesecurities$344,962K Stock-based compensationexpense, including...$17,586K Other currentliabilities$10,984K Accounts payable$4,598K Non-cash lease expense$1,176K Depreciation andamortization expense$490K Payment of issuancecosts for shares...$6,514K Net cash used ininvesting activities-$155,760K Canceled cashflow$344,962K Net cash used inoperating activities-$146,716K Canceled cashflow$34,834K Purchases of marketablesecurities$500,722K Net loss-$162,451K Non-cash interest incomeon marketable...-$6,292K Other assets andlong-term deposits$6,145K Prepaid expenses andother current assets$5,418K Operating leaseliabilities-$1,244K

Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals, Inc. (OLMA)